Jinshi Asia Pharmaceutical announced that Zhejiang Dier Pharmaceutical Co., Ltd., a wholly-owned second-level subsidiary of the company, participated in the 12th batch of nationally organized drug centralized procurement tenders. According to the announcement of the proposed selection results issued by the Joint Procurement Office, Dier Pharmaceutical's diclofenac sodium sustained-release tablets will be selected for this centralized volume procurement. The planned sales revenue for this product in 2025 was 6.2231 million yuan, accounting for 0.60% of the company's 2025 revenue.

Zhitongcaijing · 2d ago
Jinshi Asia Pharmaceutical announced that Zhejiang Dier Pharmaceutical Co., Ltd., a wholly-owned second-level subsidiary of the company, participated in the 12th batch of nationally organized drug centralized procurement bidding. According to the announcement of the proposed selection results issued by the Joint Procurement Office, Dier Pharmaceutical's diclofenac sodium sustained-release tablets will be selected for this centralized volume procurement. The planned sales revenue for this product in 2025 was 6.2231 million yuan, accounting for 0.60% of the company's 2025 revenue.